Brian is currently the Director of Biology at the Novo Nordisk Research Center in Indianapolis, IN USA, which is a Transformational Research Unit, a satellite research center for Novo Nordisk. Brian works at the interface of medicinal chemistry, in vitro biology, and in vivo pharmacology.

This presentation will provide an overview of the journey from discovery to clinic for the semaglutide molecule. The biology of GLP-1, including incretin action and food intake effects will be presented. The semaglutide molecule and mechanism of action will be described as well as the major development activities & milestones, including highlights from the Semaglutide Treatment Effect in People with obesity Programme, STEP, clinical studies.